EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy.
作者信息
Poonia Seerat, Berge Eamon M, Aisner Dara L, Damek Denise, Doebele Robert C
机构信息
School of Medicine, University of Colorado School of Medicine, Aurora, CO.
Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO.
出版信息
Clin Lung Cancer. 2014 Sep;15(5):387-9. doi: 10.1016/j.cllc.2014.04.005. Epub 2014 May 15.
Abstract
摘要
相似文献
1
EGFR exon 19 deletion mutations and systemic/central nervous system miliary metastasis: clinical correlations and response to therapy.表皮生长因子受体（EGFR）第19外显子缺失突变与全身/中枢神经系统粟粒性转移：临床相关性及治疗反应
Clin Lung Cancer. 2014 Sep;15(5):387-9. doi: 10.1016/j.cllc.2014.04.005. Epub 2014 May 15.
2
Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better.厄洛替尼治疗肺癌脑膜癌病：越多越好。
Ann Oncol. 2014 Oct;25(10):2093-2094. doi: 10.1093/annonc/mdu261. Epub 2014 Jul 23.
3
High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well.两例非小细胞肺癌伴软脑膜转移患者应用高剂量脉冲式厄洛替尼治疗的报告——其中 1 例胸部肿瘤显著缩小。
Lung Cancer. 2013 Apr;80(1):102-5. doi: 10.1016/j.lungcan.2012.12.024. Epub 2013 Feb 1.
4
EGFR exon-level biomarkers of the response to bevacizumab/erlotinib in non-small cell lung cancer.表皮生长因子受体外显子水平生物标志物与非小细胞肺癌贝伐珠单抗/厄洛替尼治疗反应的相关性。
PLoS One. 2013 Sep 10;8(9):e72966. doi: 10.1371/journal.pone.0072966. eCollection 2013.
5
Erlotinib response in an NSCLC patient with a novel compound G719D+L861R mutation in EGFR.一名非小细胞肺癌患者携带表皮生长因子受体（EGFR）新型复合突变G719D+L861R对厄洛替尼的反应
J Thorac Oncol. 2013 Sep;8(9):e83-4. doi: 10.1097/JTO.0b013e31829ceb8d.
6
Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.非小细胞肺癌患者进行常规 EGFR 分子分析是可行的：753 例患者外显子 18-21 测序结果及其后续临床结局。
Lung. 2013 Oct;191(5):491-9. doi: 10.1007/s00408-013-9482-4. Epub 2013 Jun 9.
7
Combination treatment with bevacizumab plus erlotinib for meningeal carcinomatosis of afatinib-resistant EGFR mutated lung cancer without T790M mutation: a case report.贝伐珠单抗联合厄洛替尼治疗阿法替尼耐药 EGFR 突变型肺癌脑膜转移且无 T790M 突变：一例报告。
Ann Palliat Med. 2022 Aug;11(8):2745-2750. doi: 10.21037/apm-21-1885. Epub 2021 Nov 17.
8
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.韩国非小细胞肺癌患者中表皮生长因子受体外显子 19 和 21 突变与吉非替尼或厄洛替尼疗效的差异。
J Cancer Res Clin Oncol. 2011 Apr;137(4):687-94. doi: 10.1007/s00432-010-0928-2. Epub 2010 Jun 16.
9
EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.表皮生长因子受体（EGFR）E709_T710缺失并插入D：非小细胞肺癌中一种罕见但可能对EGFR抑制剂敏感的突变
J Thorac Oncol. 2012 Oct;7(10):e19-20. doi: 10.1097/JTO.0b013e3182635ab4.
10
Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.复合 EGFR 突变与 EGFR 酪氨酸激酶抑制剂的反应。
J Thorac Oncol. 2013 Jan;8(1):45-51. doi: 10.1097/JTO.0b013e3182781e35.
引用本文的文献
1
Osimertinib is associated with improved outcomes in pre-treated non-small cell lung cancer leptomeningeal metastases: A systematic review and meta-analysiss.奥希替尼与经治的非小细胞肺癌软脑膜转移患者预后改善相关：一项系统评价和荟萃分析。
Heliyon. 2024 Apr 17;10(9):e29668. doi: 10.1016/j.heliyon.2024.e29668. eCollection 2024 May 15.
2
Imaging Pattern of Diffuse Intrapulmonary Metastases in Lung Cancer Was Associated with Poor Prognosis to Epidermal Growth Factor Receptor Inhibitors.肺癌中弥漫性肺内转移的影像学特征与表皮生长因子受体抑制剂的预后不良相关。
Cancer Manag Res. 2020 Nov 17;12:11761-11772. doi: 10.2147/CMAR.S261983. eCollection 2020.
3
[Lung Adenocarcinomas with Pulmonary Miliary Metastases: A Case Report and Literature Review].[伴有肺粟粒样转移的肺腺癌：1例报告及文献复习]
Zhongguo Fei Ai Za Zhi. 2019 Dec 20;22(12):798-804. doi: 10.3779/j.issn.1009-3419.2019.12.11.
4
Clinicopathologic Characteristics, Treatment Outcomes, and Acquired Resistance Patterns of Atypical EGFR Mutations and HER2 Alterations in Stage IV Non-Small-Cell Lung Cancer.晚期非小细胞肺癌中不典型 EGFR 突变和 HER2 改变的临床病理特征、治疗结果和获得性耐药模式。
Clin Lung Cancer. 2020 May;21(3):e191-e204. doi: 10.1016/j.cllc.2019.11.008. Epub 2019 Nov 21.
5
Patterns of spread and prognostic implications of lung cancer metastasis in an era of driver mutations.驱动基因突变时代肺癌转移的扩散模式及预后意义
Curr Oncol. 2017 Aug;24(4):228-233. doi: 10.3747/co.24.3496. Epub 2017 Aug 31.
本文引用的文献
1
EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung.脑内 EGFR 突变型肺癌伴 T790M 获得性耐药和肺部组织学转化。
J Natl Compr Canc Netw. 2013 Sep 1;11(9):1040-4. doi: 10.6004/jnccn.2013.0126.
2
Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.III 期研究阿法替尼或顺铂加培美曲塞治疗 EGFR 突变的转移性肺腺癌患者。
J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1.
3
Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.吉非替尼诱导间质性肺病后成功行 EGFR-TKI 重挑战治疗脑膜转移癌。
Jpn J Clin Oncol. 2013 Apr;43(4):422-5. doi: 10.1093/jjco/hyt012. Epub 2013 Feb 13.
4
Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.厄洛替尼诱导的间质性肺病后肺腺癌脑膜转移再次成功厄洛替尼治疗：病例报告及文献复习。
Lung Cancer. 2012 Aug;77(2):464-8. doi: 10.1016/j.lungcan.2012.04.013. Epub 2012 May 12.
5
Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis.非小细胞肺癌伴弥漫性肺内癌病频繁出现 EGFR 突变。
Eur Respir J. 2013 Feb;41(2):417-24. doi: 10.1183/09031936.00006912. Epub 2012 Apr 20.
6
Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.非小细胞肺癌脑膜转移患者的临床结局：冈山大肺癌研究组。
Lung Cancer. 2012 Jul;77(1):134-9. doi: 10.1016/j.lungcan.2012.03.002. Epub 2012 Apr 7.
7
Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features.非小细胞肺癌伴 EGFR 突变的脑转移瘤：外显子 19 缺失对影像学特征的影响。
Lung Cancer. 2012 Jul;77(1):64-9. doi: 10.1016/j.lungcan.2011.12.017. Epub 2012 Feb 13.
8
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.厄洛替尼对比标准化疗用于治疗欧洲晚期 EGFR 突变阳性非小细胞肺癌患者的一线治疗（EURTAC）：一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.
9
Miliary never-smoking adenocarcinoma of the lung: strong association with epidermal growth factor receptor exon 19 deletion.肺的不典型腺瘤样增生型腺癌：与表皮生长因子受体外显子 19 缺失有很强的关联性。
J Thorac Oncol. 2011 Jan;6(1):199-202. doi: 10.1097/JTO.0b013e3181fb7cf1.
10
Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma.肺腺癌中弥漫性、随机性肺转移，包括粟粒性转移，与表皮生长因子受体突变相关。
Cancer. 2011 Feb 15;117(4):819-25. doi: 10.1002/cncr.25618. Epub 2010 Sep 30.
Zotero 插件